Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity

US10512634B2 · kind B2 · utility

Assignee

• Kancera AB · SE

Inventors

• Johan Schultz · Stockholm, SE
• Jan Vågberg · Sollentuna, SE
• Elisabeth Olsson · Sollentuna, SE
• Katarina Farnegardh · Ekerö, SE
• Mattias Jonsson · Uppsala, SE
• Kristin Hammer · Sollentuna, SE
• Lars Krüger · Huddinge, SE

Key dates

• Filing date: May 11, 2015
• Grant date: Dec 24, 2019
• Expiry date: May 11, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y305/01098
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.